Expert Perspectives on the Evolving Treatment Landscape of Multiple Myeloma

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.

Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

The panel debates the options for treatment of late relapsed multiple myeloma.

Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.

Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.

The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.

Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.

Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.

Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.

Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.

Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.

The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.